New German bill to end pharmaceutical price "manipulation" in Germany
This article was originally published in Scrip
The German authorities will seek compensation from pharmaceutical companies that "manipulated" their medicine prices in order to try to offset the discounts that they were obliged to offer to health insurers. The provision is part of Germany's new bill on the Reorganization of the Pharmaceutical Market (Arzneimittelmarkt-Neuordnungsgesetz; Amnog)which was last week finalised by the parliament and which will come into effect in January 2011.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.